Skip to main content

Table 2 Mixed relative treatment effects of major adverse cardiovascular event and composite renal events among urate lowering agents

From: Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials

MACE; RR (95% CI)
Rasburicase - - -
1.69
(0.79, 3.63)
Febuxostat 0.82
(0.52, 1.32)
0.62
(0.35, 1.11)
2.92
(1.25, 6.78)
1.72
(0.94, 3.17)
Allopurinol 0.75
(0.47, 1.21)
1.14
(0.59, 2.22)
0.68
(0.46, 0.99)
0.39
(0.23, 0.66)
Placebo/no ULT
Composite renal events; RR (95% CI)
  1. CI Confidence interval, MACE Major adverse cardiovascular events, RR Risk ratio, ULT, Urate-lowering therapy agents
  2. Comparisons are read from left to right for both MACE and composite renal events. For example; allopurinol had lower composite renal events with RR (95% CI) of 0.39 (0.23, 0.66) compared with placebo/no ULT, and lower MACE with RR (95% CI) of 0.75 (0.47, 1.21) compared with placebo/no ULT
  3. Bold font indicates statistical significance